Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has solid fundamentals for a short-term investment strategy.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is one of the best yield companies with high dividend expectations.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • For the past twelve months, EPS forecast has been revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Weaknesses
  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's enterprise value to sales, at 3.89 times its current sales, is high.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
NOVARTIS-1.75%206 001
JOHNSON & JOHNSON-8.53%342 779
PFIZER3.98%220 295
ROCHE HOLDING LTD.-5.90%203 399
MERCK AND COMPANY11.09%169 328
AMGEN10.27%127 577
ABBOTT LABORATORIES13.46%113 519
SANOFI0.36%105 659
BAYER-9.77%101 133
GLAXOSMITHKLINE17.81%101 063
ELI LILLY AND COMPANY6.59%97 721
NOVO NORDISK A/S-4.90%96 291
BRISTOL-MYERS SQUIBB COMPAN..-7.18%92 973
ASTRAZENECA9.53%92 795
CELGENE CORPORATION-18.23%62 176
ALLERGAN PLC7.51%59 628
More Results
Financials ($)
Sales 2018 51 864 M
EBIT 2018 12 767 M
Net income 2018 9 611 M
Debt 2018 13 675 M
Yield 2018 3,64%
P/E ratio 2018 16,23
P/E ratio 2019 20,15
EV / Sales 2018 4,24x
EV / Sales 2019 4,08x
Capitalization 206 B
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart NOVARTIS
Duration : Period : Day
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Duration : Period : Week
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders